Functional ability: independence with activities of daily living at discharge from hospital · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Galantamine leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 26 weeks compared with placebo (high certainty).
1 finding from 1 review
Functional performance and activities of daily living at 26 weeks ADCS‐ADL and DAD · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (moderate certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Outcomes No of participants (studies)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of delirium during hospital admission validated diagnostic instruments1 3693 participants (14 studies)
The intervention probably leads to lower incidence of delirium during hospital admission validated diagnostic… (moderate certainty).
1 finding from 1 review
Intervention not reported
Inpatient mortality 2640 participants (10 studies)
The intervention showed no clear difference in inpatient mortality 2640 participants (10 studies) (low certainty).
1 finding from 1 review
Intervention not reported
New diagnosis of dementia (at any time point after randomisation) Not measured
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found